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Background: Denmark has implemented a comprehensive, nationwide pharmaceutical information system, and
this system has been evaluated by the Danish Council of Ethics. The system can be seen as an exemplar of a
comprehensive health information system for clinical use.
Analysis: The paper analyses 1) how informed consent can be implemented in the system and how different
implementations create different impacts on autonomy and control of information, and 2) arguments directed
towards justifying not seeking informed consent in this context.
Results and Conclusion: Based on the analysis a heuristic is provided which enables a ranking and estimation of
the impact on autonomy and control of information of different options for consent to entry of data into the
system and use of data from the system.
The danger of routinisation of consent is identified.
The Danish pharmaceutical information system raises issues in relation to autonomy and control of information,
issues that will also occur in relation to other similar comprehensive health information systems. Some of these
issues are well understood and their impact can be judged using the heuristic which is provided. More research is,
however needed in relation to routinisation of consent.
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Information systems
Information systems holding data on all patients in a
given health care system are being developed worldwide.
The most ambitious plans envisage a system holding the
complete patient record with all attendant data (lab
results, imaging data, genetic data etc.) within the sys-
tem, but such a system has not yet been implemented in
any large scale health care system. Such information sys-
tems raise many ethical and legal issues. In the present
paper we analyse some of these issues, especially issues
concerning informed consent. The starting point is a na-
tionwide pharmaceutical information system that has
already been implemented in Denmark. By focusing on a* Correspondence: ploug@hum.aau.dk
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distribution, and reproduction in any mediumconcrete, already existing system we hope to be able to
provide an analysis based more in clinical and adminis-
trative reality than in speculation about the future.
There is a substantial literature on the use of routinely
collected patient data for research purposes, but the lit-
erature on the ethical issues raised by the collection and
use of comprehensive patient data for treatment and
diagnostic purposes is more limited. The so far unsuc-
cessful efforts of the English National Health Service to
share patient information electronically across all ser-
vices has generated some ethical debate, [1-4] as has
similar initiatives in other countries [5]. In this paper we
hope to deepen this debate by showing that issues of
consent in this context may be considerably more com-
plicated than they may initially appear. There are many
differences between the research context and the clinical
context and many of them are relevant in relation to the
kind of information systems we analyse here. Although
the information in these systems is very useful fortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ing the systems is not to provide knowledge, or to pro-
vide general public benefit, but to provide direct benefit
to individual patients. These systems involve people’s
health related interests much more directly than most
research databases do. Another very important differ-
ence is that the main purpose of implementing the sys-
tem necessarily involves using the information it
contains, and the inferences that can be drawn from this
information in a person-identifiable way. Anonymity is
not an option and privacy interests can therefore not be
protected by anonymising. This entails that some of the
analyses provided in the literature on research databases
may not be transferable to the present, clinical context.
The paper falls in 3 sections. We first briefly describe
the comprehensive Danish pharmaceutical system and the
reasons given for implementing it. In the second part we
analyse issues of autonomy and informed consent raised
by the introduction of the system and provide a heuristic
for classifying these issues in a three dimensional space of
relevant considerations. In this second part of the paper
we also discuss some arguments raised by the Danish
Council of Ethics and show how they can be encompassed
by our heuristic. The final part of the paper then considers
whether the tension between respect for autonomy and
the reasons for introducing the system generate a true
ethical dilemma, and discuss further problems created by
a possible routinisation of informed consent.
The paper provides a heuristic for analysing these issues
which is of value for anyone who thinks that autonomy is
important, because the heuristic ranks possible models for
informed consent in relation to their impact on autonomy.
We do not purport to ‘solve’ the ethical issues since that
would require a determination of exactly how important
personal autonomy is in relation to all other relevant eth-
ical considerations and values. Such a determination is
outside the scope of this paper. Our heuristic is never the
less of value, since it provides a detailed account of the ef-
fect of different consent arrangements on one side of the
balancing between autonomy and other considerations.
This should allow decision-makers to have a clearer view
of what they are sacrificing in choosing consent arrange-
ments that do not fully protect autonomy.
The shared medicine profile
Since the passing of the law on personal, electronic, medi-
cine profiles in 2003, the Danish Medicines Agency – an
agency under the Ministry of Interior and Health – has
registered the personal “use” of prescription medicine
among Danes on the basis of reports from all Danish phar-
macies (see below for a discussion of “use”) [6,7]. The
resulting database feeds information into two separate
personal records, the Medicine Profile and the Shared
Medicine Profile.The Medicine Profile is an electronic record contain-
ing information about the medicine prescribed for and
bought by an individual within the last two years. Medi-
cine prescribed or given during in-patient stays is also
registered. The registration is automatic and compul-
sory. When the law was passed in 2003, pharmacists,
doctors and their assistants, the patient and the Danish
Medicine Agency were granted access to the records.
The Medicine Profile was introduced with the primary
purpose of providing doctors, patients and pharmacies
with an overview of the medication prescribed for or
given to an individual thereby enabling an improved and
consistent use of medication leading to benefit for the
individual and a reduction in public spending [6,8]. The
Medicine Profile was implemented in 2004.
The Shared Medicine Profile is an electronic record
collecting and keeping up to date information about a
patient’s medical treatment within the last two years
across electronic health records in hospitals and general
practitioner practices, electronic municipal records of
care for the elderly and the Medicine Profile. The Shared
Medicine Profile thus contains information about all
prescribed medication and any medication provided by
health care personnel along with information about the
indication on the basis of which the medication is pre-
scribed or provided. It also includes information about
any medication bought by the individual apart from
over-the-counter medication, the prescribed daily intake
and the date of termination of the medical treatment.
The health care personnel’s’ instructions of use are also
registered along with notes concerning any known non-
adherence to treatment, intolerance or allergy. Patients
can also themselves register the use of any non-
prescription medication through their electronic access
to the Medicine Profile. The Medicine Profile and the
Shared Medicine Profile both attempt to provide a rec-
ord of the medication that is used by a particular patient,
but because the vast majority of use in the community is
unsupervised there will be a, potentially significant dis-
crepancy between what is prescribed and bought and
what is actually used. This is only partly alleviated by the
possibility of patients themselves adding information to
the Shared Medicine Profile, so the official claim that
the two profiles show medication “use” is somewhat du-
bious. The Shared Medicine Profile has further extended
the groups of health care personnel with access to the
patient’s medication records. Access is now given to doc-
tors, nurses, midwives, health visitors, social and health
care assistants, workers in care for the elderly, dentists,
certain pharmacists employed at hospitals as well as
pharmacists and pharmacy assistants in community
pharmacies, as well as staff at The National Board of
Health and the Medicines Agency. Subject to the Minis-
try of Health issuing more specific rules and regulations
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the future be extended to other persons directly involved
in distributing medications to individuals in their homes.
The Shared Medicine Profile was introduced with the
explicit purpose of sharing information about a patient’s
medication between hitherto separated information sys-
tems and between health care personnel in different set-
tings. And the aim is to achieve better coordination of
medication within and across sectors, faster correction
of medication errors,early identification and consider-
ation of potential drug interactions, and a more effective
use of health care resources through reducing multiple,
identical entries in multiple parallel information systems
[7]. The Shared Medicine Profile will be fully implemen-
ted by the end of 2012.
Analysis – The shared medicine profile and
informed consent
The ethical challenge – beneficence, justice and
autonomy
The Shared Medicine Profile poses an ethical challenge –
perhaps even a dilemma. On the one hand, principles of
beneficence and non-maleficence may be taken to imply
the moral goodness of actions aimed at the prevention of
harm to others [9]. In this case the harms caused by medi-
cation errors and drug interactions. Similarly a principle of
justice may support actions aimed at distributing health
care resources without waste [9]. In this case by reducing
unnecessary prescribing and duplication of work by health
care personnel. On the other hand, the principle of respect
for autonomy is typically understood to imply a require-
ment to obtain informed consent before intervening in a
patient’s life (cf below) [9]. The Shared Medicine Profile
represents an intervention in the patient’s life. It involves
the collecting and storing of personal health information,
and the distribution of the information to a very large
group of people. The ethical challenge faced in considering
the implementation of a comprehensive health information
system such as the Shared Medicine Profile is therefore to
balance efforts to effectively gather and disseminate infor-
mation in order to prevent harm to the individual and pro-
mote a just distribution of health care resources against
proper respect for the patient’s autonomy.
Personal autonomy, respect and informed consent
Personal autonomy is associated with the ability to rule
or govern oneself, i.e. self-rule and self-government [10].
For present purposes, we shall assume that personal au-
tonomy involves two basic abilities: [11] 1) the ability to
exercise one’s cognitive capabilities in a rational forma-
tion of and identification with specific goals, values,
aims, desires and plans etc., [12-14] and 2) the ability to
pursue or implement these goals, values, aims, desires
and plans in action without the choice of action beingrestrained by forces alien to oneself [15,16]. In short,
personal autonomy involves the ability to rationally form
one’s own goals, values, plans etc., and to pursue these
without being restrained in various ways.
Furthermore, we shall assume that protecting personal
autonomy implies a requirement for a person to take steps
to ascertain that a given intervention into another per-
sons’s life does not alienate the person from his or her
goals, values and plans, and a requirement not to restrain
the person in his or her pursuit of these goals, values and
plans. That is, we take it that protecting personal auton-
omy requires that informed consent is obtained before an
intervention into another person’s life. Finally, we shall as-
sume that promoting personal autonomy is a matter of
empowering a person to rationally form and pursue goals,
values and plans unrestrained. Promoting personal auton-
omy is a matter of providing a person with the power and
the opportunity to control his or her life in formation and
pursuit of goals, values and plans. Note, very importantly,
that although the protection of personal autonomy may be
claimed to be in principle acquired through obtaining
informed consent, the specific way in which the require-
ment is implemented may promote personal autonomy to
a varying degree.
In the following we will show that the content and
presentation of a particular request for informed consent
may provide a person with control over his or her life to
very different degrees. The implicit claim is that the pro-
tection of personal autonomy through informed consent
cannot be separated from the degree to which the per-
sonal autonomy is promoted through the content and
presentation of the informed consent. Consequently, in
considering possible models of informed consent in rela-
tion to the implementation of the Shared Medicine Pro-
file we will speak of ’respect for personal autonomy’ as
being expressed through the requirement of informed
consent, and that therefore – because informed consent
both protects and promotes personal autonomy – the
’respect for autonomy’ expressed in the different models
of informed consent may vary in degree. In effect we will
speak of models of informed consent as expressing a
weaker or stronger ’respect for’ or, in this wider sense,
’protection of ’ personal autonomy.
The shared medicine profile and models of informed
consent – developing an heuristic
The implementation of the Shared Medicine Profile may
incorporate a requirement of informed consent in several
ways. The exact requirements for a valid informed consent
are a matter of serious philosophical dispute and vary le-
gally between different jurisdictions. In the following we
will assume that to be valid informed consent requires that
the person providing consent is adequately informed about
his options and their consequences, and that consent is
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rather minimal set of requirements. There are a number of
features and aspects of the implementation and use of the
Shared Medicine Profile that may be included in the con-
tent of an informed consent. Let us call these features and
aspects ‘variables’ and the options for each variable ‘values’.
The listing of ‘values’ for each ‘variable’ is not intended to
be exhaustive but identifies major options:
1. The registration of personal information about
medication, e.g. consent to:a. The registration of every prescribed medication
b.The registration of every type of prescribed
medication
c. The registration of all prescribed medication2. The use of personal information about medication,
e.g. consent to:a. The possible use of every single piece of
medication information
b.The possible use of every type of medication
information
c. The possible use of all medication information3. The access to personal information about medication,
e.g. consent to:a. The access to medication information for every
individual member of the health personnel (e.g. an
individual doctor)
b.The access to medication information for groups of
health personnel (e.g. doctors)
c. The access to medication information for all health
personnel (and potentially others)4. The exchange of personal medication information
between medical information systems, e.g. consent to:a. Every exchange of health information between
medical information systems
b. Exchange of health information between medical
information systems within the same sector
c. Exchange of health information between all health
information systems5. The authority to extend access to personal
medication information to new groups of health
personnel, e.g. consent to:a. The authority to extend access to one person
(e.g. Minister of Health)
b.The authority to extend access to a specific group
of persons (e.g. medical doctors)
c. The authority to extend access to several groups
and individuals.The above variables of informed consent are all variables
relating to the content of the informed consent. They con-
cern what the patient is ‘consenting to’. The different pos-
sible values of these variables provide the patient with
more or less control over the intervention in the patient’s
life caused by the implementation of the Shared Medicine
Profile. Assuming that respecting personal autonomy
involves providing the patient with control over interven-
tions, it follows that the inclusion of specific values for
each of these variables in the informed consent process
may either, relatively speaking, strengthen or weaken the
protection of personal autonomy. For example, if the pa-
tient consents to the access to medication information for
all health personnel then he or she will in the future not
be able to control the access to the information as effect-
ively, as if he or she had restricted the availability to only
some groups. This means that the patient will not, for in-
stance, be able to restrict access to sensitive information
only to health care personnel that he or she trusts. This
clearly weakens the protection of personal autonomy. It is
important to note that we are not claiming that increased
control over information is necessarily welfare maximis-
ing. A person may clearly use this control contrary to his
or her own interests. What we are claiming is that
increased control over personal information increases per-
sonal autonomy. This is, we submit, close to an analytical
truth.
In the following we will reduce these five variables to
two, ‘registration’ and ‘use’. The reasons for this are
primarily: 1) That ‘access’, ‘exchange’ and ‘authority to
change’ can be seen as aspects of ‘use’ of information, e.
g. that a restriction to a particular group of health care
personnel is a restriction of a specific use of the medica-
tion information, and 2) that in the Danish context the
Shared Medicine Profile operates within a predomin-
antly public health care system with clear lines of polit-
ical accountability. Issues concerning ‘exchange’ and
‘authority to change’ are thus less prominent.
There are, however, other features of the Shared Medi-
cine Profile that may influence the strength of the pro-
tection of personal autonomy through the informed
consent process. In general, the way in which informa-
tion is presented or provided will influence an indivi-
dual’s possibility of making informed choices, and
therefore also influence the individual’s ability to control
his or her life in accordance with the individual’s own
goals and values. The validity of informed consent relies
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having understood this information. The likelihood of
this being attained depends on a large number of factors
including an appropriate amount of information being
given, the information being of high quality and rele-
vance, and the information being delivered in a way that
maximises the possibility that the patient will under-
stand the information [17-20]. Information about the
Shared Medicine Profile may be disseminated in various
ways, and we will assume that the likelihood of adequate
understanding increases if the information is delivered
in a personal interaction. And we will assume, that very
general information campaigns are likely to be the least
effective. We thus have a composite variable reflecting
the likelihood of good understanding of the information
provided (we assume that the information provided is in
all circumstances adequate and of high quality):
6. The adequacy of the information process, e.g.a. The information is provided personally by health
personnel as part of the informed consent process
b.The information is provided through leaflets
distributed by health personnel
c. The information is provided through general
information campaignsPersonal interaction increases the possibility that a
health care professional may exert undue influence on a
patient’s choice. We will in the following assume that
this risk can be mitigated by professional regulation, and
that it is overall more likely that a valid informed con-
sent takes place when there is personal interaction as
part of the informed consent process.
This list of variables and their possible values is not
exhaustive. They represent an attempt to capture some
of the features and aspects of the Shared Medicine Pro-
file important for the informed consent process. Other
variables could have been taken into account. Thus there
is a longstanding discussion of the exact informational
requirements for valid informed consent [21-26]. This is
not unimportant but we are here focusing on how the
more specific features and aspects of the Shared Medi-
cine Profile are relevant to informed consent.
We have so far identified three fundamental variables –
‘registration’, ‘use’ and ‘adequacy of information’ – relevant
for the implementation of comprehensive health informa-
tion systems such as the Shared Medicine Profile. Al-
though the list of variables and their possible values may
not be exhaustive, there is a particular reason for the in-
clusion of these variables and these values. Thus it seems
to hold that the degree of protection of personal auton-
omy provided by choosing certain variables and certain
values logically dominates the protection provided bycertain other sets of variables and values, where one
model of informed consent, say A, logically dominates an-
other, say B, if and only if the protection of personal au-
tonomy entailed by B is fully included in A, i.e. if A
provides a protection of personal autonomy which is
greater than B. In other words, the patient’s control over
interventions into his or her informational domain based
on agreeing to some of these variables and values through
informed consent dominates the control over such inter-
ventions based on choosing another set of these variables
and values. This is easily seen. Thus the control gained if
the patient has to give informed consent to every registra-
tion (1.a) and every use of information (2.a), clearly domi-
nates the control gained by only having to give a general
consent to registration (1.c) and use (2.c) of information.
In fact, it seems as if the combination of requiring consent
to both the registration (1.a) and use (2.a) of every piece of
medication information provides a degree of control over
personal medication information that dominates the con-
trol gained by having to negotiate an informed consent
based on any of the remaining variables and values (1.b-c,
2.b-c, 3.a-5.c). This account of domination entails that
whereas there are combinations of values that dominate
other combinations of values, there are also combinations
of values where one set does not clearly dominate another
set (cf below); or more formally that the ranking of value
3-tuples is not complete.
The protection of autonomy gained by requiring
informed consent based on the last variable and it’s pos-
sible values (6.a-b) is not implied by the combined re-
quirement of informed consent (1.a and 2.a). This is
hardly surprising since this variable does not concern
what the patient is consenting to, but rather the way in
which the patient is being informed about the workings
of the Shared Medicine Profile.
An attempt at an ethical heuristic
The three variables identified above are fundamental in
the sense that if given particular values and incorporated
into a requirement of informed consent, they will ex-
press the strongest possible protection of personal au-
tonomy. Since these variables may take different values,
the many possible constructions of informed consent
constituted by different values of the variables may be
expressed by letting each of the variables be constituted
by an axis in a three-dimensional space (Figure 1).
The three-dimensional space illustrates the various
possibilities of constructing a requirement of informed
consent, but also raises the question of how the different
points in this space are to be ranked. At the point of the
intersection of the three axes, the protection of personal
autonomy through informed consent is evidently stron-
gest. It is less evident, however, how, for instance, the
point P is to be ranked in comparison to the point R.
P 
R 
Figure 1 The three-dimensional space of informed consent.
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strength of the protection of personal autonomy at these
points in the space of values, it seems more interesting in
terms of policy considerations to consider more well-
defined points on each of the axes. To illustrate such well-
defined points we shall here reconstruct the positions
taken by the members of the Danish Council of Ethics in
the Council’s report on the Shared Medicine Profile. In
the matrix below three well-defined points on both the
registration- and use-axes have been picked out together
with two points on the information-axis (Figure 2).Figure 2 Models of informed consent, Figure 2 consists of the three-d
points on the ’registration-axis’ (horisontal), the ’use-axis’ (vertical), a
specific point (i.e. triangle) in the three-dimensional space in which it is po
personal autonomy. The colours mark three basic clusters of points accord
’positions’ taken by members of the Danish Council of Ethics.The matrix contains 18 fields. The circled fields mark
the recommendations of members in the Danish Council
of Ethics. (The Danish Council of Ethics is not required
to reach consensus among its members before making
recommendations). The coordinates on the use-axis all
state that consent is to the use ‘by any personnel with
access to the information’. This amendment is intended
to express the view, taken by all members of the Danish
Council of Ethics, that only certain groups of health care
personnel should have access to the medication informa-
tion. In itself the limitation does not strengthen theimensional space of Figure 1 with the addition of well-defined
nd the ’information-axis’. The numbers give the ranking of the
sitioned such that the higher the number the weaker the protection of
ing to their protection of personal autonomy. The circles mark the
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vide consent to any use of medication information, then
logically speaking it does not matter if the group of
people covered by the consent is given is limited or not.
The amendment could be said, however, to strengthen
the protection of personal autonomy when considering
waivers to the requirement of obtaining consent before
use of personal medication information. All members of
the Danish Council of Ethics agree that there are situa-
tions in which the requirement of obtaining informed
consent before use of personal medication information
is trumped by other ethical concerns [8]. In those situa-
tions, limitations on the groups of people with access to
the information could be said to limit or reduce the loss
of control over access to the information, and in this
sense the limitation implies a strengthening of the pro-
tection of personal autonomy as compared to having no
limitations.
The Danish Council of Ethics makes three recommen-
dations concerning the registration and use of informa-
tion. The Council takes two different views on the
registration of personal medication information [8]. One
group recommends that the patient is given the right to
refuse the registration of personal medication informa-
tion, i.e. that one-off informed consent must be provided
before the registration of personal medication informa-
tion. Another group recommends that the registration
should be compulsory. On the use of the information
the Council members also takes two different views [8].
One group recommends that the patient is to provide
consent on every occasion of personal medication infor-
mation being retrieved and used. Another group recom-
mends that a one-off informed consent is provided to
the use of personal medication information to health
care personnel other than the patient’s own general
practitioner and The National Board of Health. Given
the different views on the registration and use we thus
end up with the three recommendations of the Council
marked by circles in the matrix.
Of special importance is the ranking of each of the
fields. The fields are ranked according to the degree of
protection of personal autonomy provided. The ranking is
marked by both numbers and colouring. The numbers
mark the ranking of the relevant field such that the higher
the number the weaker the protection of personal auton-
omy. The reasoning behind this ranking is key to fully
understanding the matrix and it’s implications – and, as
we shall see, the reasoning also on a more general level
deepens our understanding of how personal autonomy
may be interpreted and protected when implementing in-
formation systems such as the Shared Medicine Profile.
The weakest protection of personal autonomy – arguably
no protection of personal autonomy at all – occurs when
both the registration and use of personal medicationinformation is compulsory and takes place merely on the
basis of general, impersonal information about the Shared
Medicine Profile. The ranking as 18 is thus straightforward.
The ranking as 17 is less evident. However, it seems rea-
sonable to claim that the relevant ways in which a patient
is informed about the Shared Medicine Profile is less im-
portant to the protection of autonomy than being offered
the choice of consenting to the registration or to the use of
personal medication information as long as the informa-
tion about the Shared Medicine Profile is available to the
patient, i.e. as long as it is possible to make an informed
choice. The choice of giving or refusing consent allows the
patient to control the intervention of others into the life of
the patient, whereas the relevant ways in which informa-
tion about the Shared Medicine Profile is provided affects
the degree to which the patient is able to make an
informed choice. From these considerations it follows more
generally that the difference between informing the patient
through public campaigns and through personal encoun-
ters with health care professionals in itself implies a differ-
ence in ranking of only one place. This explains the
difference in ranking between 1 and 2, 3 and 4, and so on –
and therefore also in turn the difference between 17 and
18. (Note that in the special cases of the fields 17 and 18
the difference in ranking is also partly explained by the fact
that the very act of informing a patient about compulsory
registration provides the patient with an opportunity to
avoid doctors or to avoid prescriptions. Hence the informa-
tion provides a patient with an opportunity to exercise a
very limited kind of control).
This line of reasoning could be questioned on various
grounds. It may be argued that the way in which infor-
mation is provided carries different weight depending on
the variant of informed consent, i.e. field, under consid-
eration. Thus one could claim that the fields currently
ranked <1, 2, 3, 4> should be ranked <1, 3, 2, 4> with
the other rankings remaining the same. However, we
shall maintain the current ranking – not least because it
seems that valid consent before the registration or use of
personal information in practice simply cannot be
obtained without providing considerable information
about the Shared Medicine Profile. Thus the theoretical
difference between a health care professional personally
informing a patient and information only being provided
by public campaigns seems to be reduced significantly
when considering the practical circumstances of having
to obtain consent.
The additional rankings are based on a number of
considerations. As discussed above, informed consent is
supposed to be a way of protecting an individual’s ability
to form and pursue his or her own plans and goals. It
seems to follow that any construction of informed con-
sent that will extend both the available ways of control-
ling the influence of other’s on the pursuit of goals and
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courses of action is preferable. The possible models of
informed consent found in the matrix provide different
degrees of control and possibilities for pursuing the ben-
efits associated with the Shared Medicine Profile. Those
found in the fields <1,2>, <3,4>, <5,6> and <7,8> − here
paired on the basis of the same coordinates on the
registration- and use-axes and referred to by their rank-
ing – all provide the patient with some control over the
registration and use of information while at the same
time making it possible for the patient to achieve the po-
tential benefits of the implementation of the Shared
Medicine Profile, i.e. a better coordination of medication
within and across sectors, a faster correction of medica-
tion errors and an earlier identification of potential drug
interactions.
In the model of informed consent found in the fields
<1,2> the patient is given control over the registration of
every piece or type of personal medication information. By
controlling every piece or type of medication information
the patient is given very flexible control over the informa-
tion available for use by health personnel, but also and
more importantly, the patient is given flexible control over
the information potentially abused by health personnel or
otherwise lost to third parties. The abuse may happen
through people acquiring unauthorized access to the in-
formation, but also through health personnel acquiring ac-
cess by falsely or unjustifiably claiming a situation to be
among the waivers where concurrent patient consent is
not necessary. (The Danish Medicines Agency has at this
point in the implementation process reported on five cases
of unauthorized access to the Shared Medicine Profile
[8]). In the fields <1,2> the patient is also given control
over the use of personal medication information by a par-
ticular health person in a particular situation. Again, the
control over the use of information by a particular health
person in a particular situation makes it a very flexible
control. The patient is able to control whom to entrust
with personal medication information and when. In total
the construction of informed consent found in the fields
<1,2> represents a very flexible protection of the patient’s
personal autonomy in that it allows the patient to act upon
his or her own balancing of the potential benefits and
harms from having a specific piece of information regis-
tered, and from allowing a specific person to access per-
sonal medication information on a particular occasion.
In the model of informed consent found in the fields
<3,4> there is a slight weakening of the flexibility in the
patient’s control over personal medication information.
The patient retains the possibility of weighing benefits
and harms associated with having a specific, single piece
or type of personal medication information registered,
but cannot flexibly control what information a particular
person may access on a particular occasion.In the model of informed consent found in the fields
<5,6>, there is also a weakening of the flexibility in the
patient’s control. Thus the patient cannot both realise
the benefits from registering personal medication infor-
mation, and at the same time retain control over what
information that is registered. It is simply all or nothing.
Control over the pool of information that may be used
and abused is, in these fields incompatible with the real-
isation of the benefits from registering personal medica-
tion information. However, the patient is given control
over the use of personal medication information by a
particular person on a particular occasion. The reason
for ranking these fields, <5,6>, lower than the previous
fields, <3,4> and <1,2> , is simply that the combination
of values makes it impossible to both gain benefits from
registering personal medication information while at the
same time retaining a degree of control over the regis-
tration and use of personal medication information.
Thus <1,2> and <3,4> provides a stronger protection of
personal autonomy than <5,6> in virtue of providing
flexible control over information in combination with
the additional possibility of realising at least some of the
benefits associated with the implementation of the
Shared Medicine Profile. This argument in favour of the
current ranking of the relevant fields obviously presup-
poses that it is possible to realise some of the benefits
claimed to be associated with the Shared Medicine Pro-
file without having to register all of one’s personal medi-
cation information. It seems, however, that better
coordination of medication within and across sectors,
faster correction of medication errors and earlier identi-
fication of potential drug interacttions are benefits that
may to some degree be achieved without the registration
of all personal medication information (cf. below).
The model of informed consent found in the fields
<7,8> implies a further weakening of the control over
the use of personal medication information as compared
to <5,6>. All other constructions of informed consent
found in the matrix involve a weakening of the patient’s
control over personal medication information by making
either the registration or use of personal medication in-
formation compulsory. The ranking of these fields will
consequently be above 8 and below 17 – the specific
ranking may be worked out on the basis of the consid-
erations found above.
Discussion
Limits to the requirement of informed consent
In the previous section we introduced a heuristic for
developing and evaluating different possible ways of
implementing a requirement of informed consent in re-
lation to the Shared Medicine Profile. Using the heuristic
we ranked a number of possible models of informed
consent. Assuming the value of personal autonomy, the
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what reasons there are for implementing any model but
the one that provides the patient with the strongest pro-
tection of his or her personal autonomy, i.e. <1>. As
already mentioned, there are possible reasons for imple-
menting a weaker model of informed consent, and it is
to the analysis of these we now turn.
Generally speaking any requirement of obtaining
informed consent, before the intervention in a patient’s
life may be weakened or no longer apply, if one or more
of the following is the case:
1) There are insurmountable practical difficulties
associated with obtaining consent
2) The patient lacks the competence required to
provide consent,
3) There are other ethical concerns trumping the
principle of respect for autonomy,
4) The practice of obtaining informed consent in itself
undermines the protection of personal autonomy.
It is, for instance, a combination of these considera-
tions that is usually taken to justify the common practice
of sharing information without consent within the im-
mediate group of health care personnel involved in the
patient’s care. However, the information sharing in rela-
tion to the Shared Medicine Profile is much wider and
requires separate analysis and justification.
The practical difficulties associated with the imple-
mentation of informed consent clearly hinges on the
specific model of informed consent. The models provid-
ing the strongest protection of personal autonomy re-
quire that consent is obtained on many occasions,
whereas the models providing the weakest protection
only require a single valid consent. The practical difficul-
ties will also depend on the character of the informed
consent process. If it is handled as other consent pro-
cesses in clinical practice then the health care profes-
sional must – on the basis of having informed about the
Shared Medicine Profile – direct a request to the patient
to provide consent to the registration and use of the
patient’s personal medication information. This request
could alternatively be put to the patient electronically.
The Shared Medicine Profile provides the patient with
web access to the entries in his or her profile. An elec-
tronic request of consent could be transmitted via the
Shared Medicine Profile – and in case the consent is
given the transfer of information to the profile and be-
tween information systems could be automatically
initiated. Whichever way the requirement of informed
consent is implemented it seems unreasonable to char-
acterise the practical difficulties as insurmountable. Sig-
nificant, but surmountable practical difficulties cannot
as such rule out any implementation of informedconsent, although they may be relevant to further ethical
considerations of whether or not to prioritise the imple-
mentation of a given model of informed consent.
In the opinion of some members of the Danish Coun-
cil of Ethics the registration and use of personal medica-
tion information must be made compulsory for the
simple reason “that many patients will find it difficult to
grasp the advantages and disadvantages of not being
included in the Shared Medicine Profile. In particular
this would hold in relation to the group of patients (. . .)
undergoing treatment with a variety of medicines (. . .).”
[8] In the first general part of this statement the opinion
seems to be that people in general do not satisfy stand-
ard criteria of decisional competence [27-30] in that they
are considered unable to comprehend the consequences
for them of being included in the Shared Medicine Pro-
file. Unfortunately there is no further elaboration on
what particular features of the Shared Medicine Profile
that patients are supposedly, unable to grasp. There
seems to be little difference between the nature of the
intervention into a patient’s life constituted by the im-
plementation of the Shared Medicine Profile and other
medical interventions for which informed consent is
required.
As we briefly discussed above, there are strong ethical
reasons for implementing the Shared Medicine Profile.
SMP improves conditions for providing medical care in
situations of emergency, and more generally leads to bet-
ter coordination of medication within and across sectors,
faster correction of medication errors,earlier identifica-
tion of potential interactions, and reduced waste of
resources in the Health Sector. The question remains,
however, if the satisfaction of the principles of benefi-
cence and justice in the case of the Shared Medicine
Profile are inconsistent with respecting and protecting
personal autonomy through the implementation of a re-
quirement of informed consent, i.e. if we are here faced
with a true dilemma.
In order for the Shared Medicine Profile to present a
true dilemma two mutually intertwined empirical condi-
tions must be satisfied. Firstly, it has to be the case that
no single patient can reap the benefits of the Shared
Medicine Profile without registering all personal medica-
tion information. If there are individual health benefits
and reduced waste of resources to be gained from only
partial access to the patient’s personal medication infor-
mation, then the implementation of a requirement of
informed consent resulting in a limited registration of
information or limited access to use the registered infor-
mation, will not pose a hindrance to the improvement of
health care. In this case then, the implementation of a
requirement of informed consent will not be inconsist-
ent with satisfying other principles such as beneficence
and justice. The question therefore is, if there are
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patient’s information. It seems that partial access will –
at least to some extent – allow for better coordination of
medication within and across sectors, faster correction
of medication errors, earlier identification of potential
interactions, and also lead to reduced waste of the
resources going into the parallel development and main-
tenance of separate information systems in the health
care sector. Partial access to personal medication infor-
mation may be a problem in terms of discovering poten-
tial drug interactions solely on the basis of studying
medication records in the SMP, but some cases of inter-
actions may be detected on the basis of access to less
than complete personal medication information.
The second empirical prerequisite of a true dilemma
concerns the patient’s actual behaviour in terms of provid-
ing consent. If the implementation of the Shared Medicine
Profile is to pose a true dilemma, then we must be able to
rule out the possibility that adequately informed patients
voluntarily choose to consent to the registration and use
of their personal medication information. However, there
seems to be little evidence of widespread refusal of con-
sent – at least in a Danish context. On the one hand, it
does seem reasonable to expect that some consent pro-
cesses may result in the withholding of consent. On the
other hand, it does not seem as if patients generally exhibit
a restrictive behaviour in other consent processes in the
health sector. The extent to which consent will be refused
is thus hard to predict. The point still applies, however,
that if we cannot rule out the possibility that people vol-
untarily choose to provide consent, then the implementa-
tion of the Shared Medicine Profile with a requirement of
obtaining informed consent does not necessarily pose a
true dilemma.
Although the above considerations of the empirical
preconditions of a true dilemma raise some important
questions, they also point to a different sense in which
the Shared Medicine Profile poses a dilemma. The im-
plementation of the Shared Medicine Profile along with
a requirement of informed consent is de facto incompat-
ible with the maximal satisfaction of the targets of bet-
ter coordination of medication, faster correction of
medication errors,earlier identification of potential drug
interactions, and reduced waste of health care resources.
In so far as the principles of beneficence and of justice
are taken to be requirements of maximal beneficence
and justice, then the complete satisfaction of these prin-
ciples is incompatible with the satisfaction of the re-
quirement of informed consent. If the satisfaction of the
principles of beneficence and justice may be gradual or
partial, then it clearly is the case that the implementa-
tion of the Shared Medicine Profile with a requirement
of informed consent is compatible with beneficence and
justice.One might here take the position that both of the empir-
ical conditions are de facto satisfied: 1) the benefits of the
implementation of the Shared Medicine Profile can only
be realised on condition of full access to the personal
medication information and patients would generally
choose to withhold consent; and 2) that the principles of
beneficence and justice are to be the sole principles guid-
ing action. Consequently, the Shared Medicine Profile
must be implemented with a requirement of compulsory
registration and full access to the use of personal medica-
tion information. However attractive this position may
seem, it conflicts with the strong tradition in the health
care sector of giving priority to the protection of personal
autonomy in situations that exhibit a significant similarity
with this one. Thus it is common practice to accept a
patient’s refusal of therapy that medically is considered to
be appropriate, and instead provide therapy that is consid-
ered to be less adequate, but in accordance with the goals,
plans and values of the patient – even in cases where this
may lead to increased public costs. This leaves a propon-
ent of the position sketched above with two options.
Either the ethically relevant difference between clinical
practice and the implementation of the Shared Medicine
Profile has to be pointed out, or one must argue in favour
of restricting the protection of personal autonomy through
informed consent in all of these situations.
The fourth and final reason for restricting the use of
informed consent in relation to the Shared Medicine Profile
is if a requirement of informed consent undermines the
very function of the informed consent as a protection of
personal autonomy. How is that possible? The answer is
that the informed consent may lose its function as a protec-
tion of personal autonomy if it is routinised. By routinisa-
tion is meant the provision of consent as a routine action, i.
e. as an unreflected, habitual act. If the provision of consent
becomes an act of routine then it will no longer protect the
personal autonomy since the very essence of this protection
is about reflecting on the consistency of another’s suggested
intervention with one’s goals, plans and values. On the as-
sumption that routinisation may undermine the function of
informed consent as suggested here, it evidently becomes
of interest to clarify if the possible implementations of
informed consent discussed in the previous sections may
lead to the routinisation of consent. The process of provid-
ing consent before installing computer software may be
seen as an analogous case shedding some light on this
question. It seems to be a common experience that the
consent provided before installing software is routinised –
the consent is provided as an unreflective, habitual act. The
act of providing consent is simply reduced to a number of
steps that have to be taken before access to certain attract-
ive functionalities is acquired. In this case the routinisation
seems to be conditioned by four factors. First, the unmana-
geability of the extensive information on the conditions of
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provided. Third the strong desire to acquire the functional-
ities constituted by the software. Fourth, the expectation
that the conditions of use are not unreasonable. The second
factor is highly relevant when considering the possible im-
plementation of informed consent discussed previously. If
informed consent is required for every registration and use
of personal medication information, then a significant num-
ber of people will be asked to provide consent rather often.
If this model of consent is implemented such that the con-
sent is to be provided to health personnel in the course of
treatment, then the third and fourth factor are also relevant.
The provision of consent may thus be influenced by a de-
sire to start or focus upon treatment, and it seems likely
that many people will expect the actions suggested by the
health personnel – access to the patient’s personal medica-
tion information – to be in their best interest. The general
conclusion therefore seems to be that at least some of the
suggested models of informed consent may lead to the rou-
tinisation of the provision of informed consent, and hence
to the undermining of the ability of the informed consent
to protect personal autonomy. It has to be noted, however,
that this argument needs further substantiation. Routinisa-
tion ultimately refers to an empirical condition, and there-
fore has to be vindicated as such. Note also, that although
the argument from routinisation undermines extensive and
repeated use of informed consent in the implementation of
the Shared Medicine Profile, it is wholly consistent with the
assertion of the principle of respect for personal autonomy.
Thus one may hold that it exactly is because personal au-
tonomy is worthy of protection, that routinisation poses a
problem.
Conclusion
In this article we have argued that the implementation of a
comprehensive health information system such as the
comprehensive, nationwide Danish pharmaceutical infor-
mation system known as the Shared Medicine Profile
poses an ethical challenge, namely the challenge of balan-
cing efforts to effectively gather and disseminate informa-
tion in order to prevent harm to the individual and
promote a just distribution of health care resources while
at the same time respecting the patient’s autonomy.
In the face of this challenge we have considered possible
ways of implementing a requirement of informed consent
in the running of an information system such as the the
Shared Medicine Profile. To clarify the way in which dif-
ferent options impact on the protection of personal auton-
omywe have developed a general, ethical heuristic for:
1) Constructing possible models of informed consent,
and
2) Evaluating these models with respect to their impact
on personal autonomyFinally, we have considered four possible strategies for
denying a requirement of informed consent in relation
to the implementation of pharmaceutical information
systems such as the Shared Medicine Profile. In relation
to these four strategies we have argued:
1) That there are no insurmountable practical
difficulties involved in implementing a requirement
of informed consent
2) That it seems unlikely that patients should lack the
competence required to provide consent in relation
to the registering and use of personal medicine
information
3) That the implementation of pharmaceutical
information systems do not necessarily poses a
‘strong’ ethical dilemma, and
4) That the implementation of a model of informed
consent requiring the patient to provide frequent
consent may lead to the routinisation of informed
consent
With respect to any future research agenda, the fourth
conclusion is of special importance. As argued above the
routinisation of informed consent undermines the very
ability of informed consent to protect personal auton-
omy, and it seems as if routinisation poses a serious
threat to a significant sub-set of the models of informed
consent considered in this article. As far as we know the
notion has not received any attention in the literature
on medical ethics as well as within the broader frame-
work of ethics and moral philosophy.Competing interests
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